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This experimental controlled study was performed to evaluate the composition of autologous processed plasma (APP), and the effects of APP 
intra-articular injection into healthy equine metacarpophalangeal joints. The effects on joints were analysed with a short-phase protocol and 
a prolonged-phase protocol using saline-injected joints as controls. For the short protocol, horses received one intra-articular APP injection. 
Synovial fluid samples were collected prior to the injection and 3, 6, 24, 48, and 16 h after treatment. For the prolonged protocol, the joints 
received three weekly injections of APP, and samples were collected at 0, 7, 14, 21, and 28 days before APP administration. IL1-ra level was 
found to be increased in APP compared to plasma. Upon intra-articular administration of APP, transient (up to 24 h) increases in white blood 
cell (WBC) counts along with elevated protein and prostaglandin E2 (PGE2) concentrations were observed in the treated joints. Over the 28-day 
observation period, APP did not elicit changes relative to baseline levels, but WBC counts, PGE2 and chondroitin sulphate concentrations 
were lower than those found in the control. In conclusion, APP intra-articular injection induced a mild and transitory inflammatory response 
but no inflammation reaction was observed over a longer period of treatment and observation.
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Introduction
The growing participation of equine athletes in different 
sports has been accompanied by an increasing incidence of 
inflammation in the appendicular skeleton, particularly in the 
joints. In fact, osteoarthritis is a common finding in sport horses 
[31]. The demand for therapeutic options to shorten the disease 
course and reduce related sequelae has similarly increased [35]. 
It is now well recognized that arthropathies are caused by 
disruption of the balance between anabolic and catabolic events 
with a dominance of catabolism during the most advanced 
stages of the disease [9].
There is evidence indicating that interleukin-1 (IL-1) and 
tumor necrosis factor (TNF) are the most important pro- 
inflammatory cytokines in joint diseases [24]. IL-1 and TNF 
can stimulate their own production and induce chondrocytes to 
produce other cytokines, prostaglandin E2 (PGE2) and also 
matrix metalloproteases (MMP-1 and MMP-3), leading to the 
digestion of the articular cartilage extracellular matrix [6]. In 
cases of osteoarthritis, the equilibrium between IL-1 and its 
natural antagonist interleukin-1 receptor antagonist (IL-1ra) 
could favor IL-1 because little IL-1ra is produced [24]. The 
synovial fluid of patients with early osteoarthritis contains more 
IL-1 and TNF than individuals with advanced osteoarthritis 
[3]. Therefore, the introduction of agents that could block 
degenerative and inflammatory processes is of great clinical 
relevance.
Different cell types present in the osteoarthritic synovium 
could be responsible for the observed inflammation. These 
include macrophages, synovial fibroblasts, and mononuclear 
cells (as reviewed in [34]). The synovial membrane is thus a 
promising target to prevent cartilage catabolism and treat 
clinical symptoms [4]. In addition, several molecules can 
counteract the activities of IL-1 by binding to the cytokine 
itself or its receptor, thereby limiting transcription or acting 
locally at regulatory sites (as reviewed in [14]). As already 
mentioned, IL-1ra is a natural inhibitory cytokine [1] that 
competes for occupation of surface IL-1 receptors [10] and acts 
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in a dose-dependent fashion. Meijer et al. [25] demonstrated 
that physico-chemical stimulation of blood in a commercial 
syringe containing treated glass beads, incubated at 37oC for 24 
h, and centrifuged results in serum enriched with growth factors 
and anti-inflammatory cytokines, particularly IL-1ra. This 
haemoderivative known as autologous conditioned serum 
(ACS) and sold under the trade names Orthokine and irap 
(Orthogen Veterinary, Germany) has been used in equine and 
human orthopaedic therapies for treating musculoskeletal 
injuries [35].
A recent study comparing two commercial methods for 
producing ACS from equine blood (irap and IRAPII) has shown 
that the addition of heparin to total blood prior to incubation 
(processing) results in plasma with IL-1ra levels that are 
increased 1.5-fold compared to ACS [17]. Brossi et al. [7] have 
also shown that plasma obtained after blood is incubated at 
37oC for 24 h and centrifuged in regular heparinized tubes is, in 
fact, a haemoderivative with antioxidant properties called 
autologous processed plasma (APP). This reagent can elicit an 
antioxidant effect equivalent to that of ACS on stimulated 
equine synovial fluid cells. Thus, mounting evidence has 
indicated that the processing of plasma, similarly to ACS, might 
result in a haemoderivative with therapeutic activities that are 
useful for the management of musculoskeletal injuries in 
horses.
The present study was designed to evaluate the composition 
of APP. Additionally, the effects exerted by intra-articular 
injection of APP on healthy equine metacarpophalangeal joints 
and synovial fluid inflammatory markers were investigated. 
Total protein contents, nucleated cell counts, inflammatory and 
anti-inflammatory cytokines, and glycosaminoglycans (GAGs) 
were analysed.
Materials and Methods
Animals
The experimental protocol used for this study was approved 
by the Animal Care and Use Committee of School of Veterinary 
Medicine and Animal Science − University of São Paulo 
(FMVZ-USP) (protocol no. 2266/2011; date of approval: 
06/22/2011). Ten male and female mixed breed horses of 
FMVZ-USP, weighing 350 to 400 kg and 4 to 10 years of age 
were used. All animals were clinically healthy and did not have 
a history of articular disease.
In vitro and in vivo studies
During the in vitro part of this study, the horses served as 
blood donors for the production of APP. The levels of total 
protein, IL-1, Il-1ra, PGE2, interleukin-10 (IL-10), and tumour 
necrosis factor  (TNF-) in the APP were measured. These 
characteristics were compared to those of unprocessed plasma 
recovered from the same horse. 
The experimental in vivo part of this study was divided in a 
short-phase period and prolonged phase period. During the 
short phase, or hour protocol, we subjected 10 horses to a single 
4-mL injection of APP into one randomly assigned 
metacarpophalangeal joint. After 7 days, the contralateral joint 
was injected with 4 mL of saline as a control. Synovial fluid 
samples were collected immediately prior to each injection and 
3, 6, 24, 48, and 168 h after injection to determine the white 
blood cell (WBC) counts along with the total protein, IL-1, 
Il-1ra, PGE2, TNF-, and GAG levels.
The prolonged protocol, or week protocol, was started after a 
30-day rest period and included six animals. The animals 
received weekly intra-articular injections of APP in a randomly 
assigned metacarpophalangeal joint for 3 consecutive weeks as 
previously recommended for the administration of ACS [13]. As 
a control, the contralateral limbs were treated with intra-articular 
saline injections.
Synovial fluid sample collection
Synovial fluid samples were collected immediately prior to 
each APP or saline injection on days 0, 7, 14, 21, and 28 and 
analysed in a similar fashion to that for the short phase protocol. 
In both phases (i.e., the short and prolonged protocols) of the in 
vivo study, arthrocentesis was performed through the 
sesamoidean collateral lateral ligament using 21 G1.1/4" 
hypodermic needles (Becton, Dickinson and Company, USA) 
as previously described by Misheff and Stover [26]. The 
puncture site was aseptically prepared using povidone iodine 
scrubs (Riodeine; Rioquímica, Brazil) and 70% alcohol. 
APP preparation
APP acquisition began with the aseptic collection of 
approximately 20 mL of blood via the left jugular vein into 
tubes containing sodium heparin (Vacutainer; Becton, Dickinson 
and Company). The samples were incubated at 37oC for 24 h in 
5% CO2. The plasma was then collected and transferred to a 
sterile Falcon tube (TTP Techno Plastic Products, Switzerland) 
and centrifuged at 300 × g for 10 min at 24oC to remove cellular 
debris. The supernatant was transferred to another sterile 
Falcon tube and further centrifuged at 900 × g for 10 min at 
24oC. The APP was aspirated using a sterile needle and syringe, 
and immediately injected through a 0.22-m Millipore microfilter 
(Millex-GV; Merck Millipore, Ireland). The entire procedure 
was performed under a laminar flow hood to ensure the sterility 
of the final product.
Synovial fluid analysis 
WBC counts in the synovial fluid were determined using in 
natura aliquots in a Neubauer chamber (Belden, Germany). 
Differential counts were performed using smears stained with 
May-Grümwald-Giemsa dye. The total protein levels in the 
synovial fluid and APP were measured using the biuret method 
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Table 1. Composition of plasma prior to processing and 
autologous processed plasma (APP) samples
Plasma APP
Total protein (g/dL)
TNF- (pg/mL)
IL-1 (pg/mL)
IL-1ra (pg/mL)
IL-10 (pg/mL)
PGE2 (pg/mL)
  6.10 ± 0.44
  456.1 ± 179.5
       < 15
     < 4
  675.2 ± 308.0
38.71 ± 6.42
  6.00 ± 0.37
  522.9 ± 197.6
       < 15
  128.9 ± 52.7*
481.25 ± 263.5
34.32 ± 1.34
*Statistically significant difference (p < 0.05).
with an automated biochemical analyser (Randox Laboratories, 
UK). 
IL-1, IL-1ra, and TNF- levels were measured with an 
ELISA using commercial kits. For IL-1 quantification, the 
USCN Life Science (China) E90569Eq kit was used. This is a 
sandwich enzyme immunoassay specific for equine IL-1. 
IL-1ra was measured with a Quantikine MRA00 kit (R&D 
Systems, USA) that is also a quantitative sandwich enzyme 
immunoassay previous validated for horses [13]. TNF- was 
measured with an equine-specific DuoSet ELISA system 
produced by R&D Systems (DY1814).
Eicosanoids in the synovial fluid were quantified with an 
ELISA using a 514010 Prostaglandin E2 EIA kit (monoclonal; 
Cayman Chemical Company, USA). In brief, the plates were 
pre-coated with goat polyclonal anti-mouse IgG, and incubated 
with tracer acetylcholinesterase-linked PGE2, a monoclonal 
antibody specific for PGE2, and sample containing free PGE2. 
As the concentration of PGE2 tracer is held at a constant level 
and the amounts of PGE2 in different samples vary, the tracer 
bound to the specific antibody is inversely proportional to the 
PGE2 concentration of the sample [2,30]. 
Hyaluronic acid (HA) and chondroitin sulphate (CS) 
concentrations were determined as previously described [23]. 
In brief, synovial fluid samples (100 L) were subjected to 
proteolysis and debris was removed by centrifugation (3,000 × 
g for 15 min at 24oC). The supernatant was then freeze-dried 
and resuspended in water (50 L). Aliquots (5 L) were 
subjected to agarose gel electrophoresis. The gels were stained 
with toluidine blue (Quemis do Brasil, Brazil) in 1% acetic acid 
and then in sodium acetate buffer (pH 5). Band density was 
quantified by densitometry (VisionWorks LS; UVP, USA). To 
compensate for possible dilution of the synovial fluid samples, 
urea concentrations were measured by urease-glutamate 
dehydrogenase using an automated biochemical analyser 
(Randox) as previously described [2,15,23].
Statistical analysis
Data were evaluated for normality using the Kolmogorov- 
Smirnov test. Afterwards, paired t-tests and an ANOVA 
followed by Tukey test were used to compare the APP with the 
control group. GraphPad Instat 3 software (GraphPad, USA) 
was used to perform the statistical analyses. P values < 0.05 
were considered significant.
Results
Analysis of plasma and APP
Table 1 shows the total protein, TNF-, IL-1, IL-1ra, IL-10, 
and PGE2 concentrations in plasma prior to processing and in 
the APP samples. Only the IL-1ra concentration differed, which 
was increased in APP compared to the unprocessed plasma. 
IL-1 levels in both unprocessed plasma and APP as well as 
IL-1ra concentrations in plasma were below the detection limit 
of the assays.
In vivo effects of APP intra-articular administration
During the short-phase protocol, synovial fluid acquired from 
the joints that were injected with APP had increased WBC 
counts compared to the saline-injected joints at 3, 6, 24, and 48 
h (p < 0.05) with a predominance of polymorphonuclear cells at 
3 and 6 h. The APP-treated joints also exhibited significantly 
increased concentrations of PGE2 and total protein at 3 and 6 h, 
and CS at 24 h (Fig. 1). In contrast, the HA concentrations did 
not vary between the groups (Fig. 2).
As shown in Figs. 1 and 3, APP-treated joints had increased 
WBC counts at 6 h compared to baseline levels. Additionally, 
protein and PGE2 concentrations were increased at 3 and 6 h, 
and CS and IL-1ra levels were elevated at 24 h (p < 0.05). In the 
saline-injected joints, increases relative to the baseline were 
observed for WBC counts and CS concentrations at 24 and 48 h, 
IL-1ra at 24 h, and PGE2 at 6 h. Protein concentrations did not 
significantly vary in the saline-injected joints (p < 0.05).
During the prolonged-phase protocol (28 days), synovial 
fluid samples from the APP-treated joints had lower protein 
concentrations and WBC counts with a predominance of 
mononucleated cells on days 14, 21, and 28 compared to 
saline-injected joints. Decreased PGE2 concentrations were also 
noted on day 28 (p < 0.05). Furthermore, the CS concentrations 
were reduced on days 7, 14, and 21 (p < 0.05; Figs. 3 and 4). HA 
levels did not differ significantly between the two groups as 
observed during the short-phase protocol (Fig. 2).
Over the 28-day observation period, no changes in WBC 
counts or protein and PGE2 concentrations relative to baseline 
levels were observed in the APP-treated joints. In contrast, 
WBC counts at 14, 21, and 28 days, and PGE2 concentrations at 
28 days (p < 0.05) were elevated in the saline-injected joints 
(Fig. 4). Compared to baseline levels, CS and HA concentrations 
did not vary in either APP-treated or saline-injected joints 
(Figs. 2 and 4). Likewise, no variations in TNF- or IL-1 
concentrations were observed in either the APP-treated or 
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Fig. 1. Nucleated cell counts (WBC, cell/L) and concentrations (expressed as average ± standard error [SE]) of total protein, 
prostaglandin E2 (PGE2), and chondroitin sulphate (CS) from APP-treated and saline-injected groups during the short-phase protocol 
(0∼168 h). All concentrations are expressed as urea ratios to correct for possible fluid volume variations. *Statistically significant 
differences compared to the saline-injected (control) group (p < 0.05); †Statistically significant differences compared to the baseline 
levels for each group (p < 0.05).
saline-injected joints during the short- and long-term protocols 
(Fig. 3).
Discussion
Haemoderivatives enriched in anti-inflammatory cytokines 
and growth factors were introduced for treating joint diseases in 
both humans and animals. These preparations are usually 
administered by arthrocentesis, a routine procedure performed 
for both diagnostic and therapeutic purposes. Nonetheless, 
arthrocentesis per se requires perforation of the synovial 
membrane and causes cell rupture along with a local 
inflammatory reaction [39]. This trauma may lead to the release 
or activation of several biomarkers involved in inflammation 
and possibly cartilage degradation, thus altering the synovial 
fluid composition [40]. To avoid or minimize interference due 
to the arthrocentesis procedure itself, each APP-treated joint in 
the present study was compared to its contralateral joint that 
received saline injections and was used as a paired control.
Data from the present study showed that the only difference in 
composition between unprocessed plasma and APP was the 
IL-1ra concentration, which was increased more than 100 
times. APP was free from inflammatory cytokines that might 
potentially cause adverse effects (see Table 1). Rutgers et al. 
[33] determined the cytokine profile of ACS and also found 
increased levels of anti-inflammatory cytokines, such as IL-1ra 
and IL-10, and pro-inflammatory cytokines after processing. 
Nevertheless, it should be noted that the ACS produced by 
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Fig. 2. Agarose gel electrophoresis of glycosaminoglycans isolated from equine synovial fluid samples collected during the short- and 
prolonged-phase protocols (A and B), and hyaluronic acid concentrations from APP-treated and saline-injected groups during the short-
and prolonged-phase protocols (C and D). All concentrations are expressed as urea ratios to correct for possible fluid volume variations.
CS: chondroitin sulphate, HA: hyaluronic acid, HAS: hyaluronic acid standard, CSS: chondroitin sulphate standard. 
Rutgers was obtained with 6 h of incubation while our APP was 
acquired after a 24-h incubation of the blood sample. This 
possibly resulted in different products. As demonstrated by 
Hraha et al. [17], the incubation time is a key factor for 
producing molecules of therapeutic interest in ACS, and 
shortened incubation times can adversely affect the composition 
of the blood derivative.
APP intra-articular administration seemed to promote a mild, 
transient, inflammatory response since increased WBC counts 
along with elevated PGE2 and total protein concentrations were 
observed within 3∼6 h compared to saline-injected joints. 
These markers returned to baseline levels at 24∼48 h. In 
contrast, the synovial fluid CS concentration increased 
significantly 24 h after arthrocentesis in both the APP-treated 
and saline-injected joints, but more so in the APP-treated joints. 
This response over time suggests that inflammatory mediators 
may stimulate cartilage catabolism, leading to CS increases in 
synovial fluid.
During the 28-days observation period with weekly injections 
of APP or saline, APP did not cause any increases in 
inflammatory or catabolism markers. WBC counts as well as 
PGE2, total protein, and CS concentrations were low throughout 
the experimental period. On the contrary, saline injections 
induced mild inflammatory changes, as indicated by increased 
WBC and PGE2 levels, while APP did not. It seems that this 
long-term, mild, inflammatory response induced by 
arthrocentesis and saline was inhibited by APP.
Inflammatory responses after saline injection have been 
previously been detected in equine synovial fluid [36]. 
Nevertheless, saline was preferred as a control instead of 
unprocessed plasma because the latter is a complex mixture of 
proteins and soluble factors, with a wide and not fully known 
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Fig. 3. Cytokine profiles of synovial fluid from the APP-treated 
and saline-injected groups collected during the short-phase and 
prolonged-phase protocols. All concentrations are expressed as 
urea ratios to correct for possible fluid volume variations. TNF: 
tumor necrosis factor alpha, IL-1ra: interleukin 1 receptor 
antagonist, d: day. †Statistically significant differences compared 
to baseline values (p < 0.05).
range of therapeutic properties [20,29]. Thus, unprocessed 
plasma is a non-inert product that may be unsuitable for the 
desired purposes.
In the synovial fluid of healthy equine joints, an average of 
50∼500 WBC/L with 90% mononuclear cells and 10% 
polymorphonuclear cells [9] is usually considered normal. 
Lower WBC counts have been reported for metacarpophalangeal 
synovial fluid (390 WBC/L) in agreement with our results 
(initial 131∼343 WBC/L) [22]. In four out of ten animals, 
substantial increases in WBC counts (up to 29,000 WBC/L) 
with 88% polymorphonuclear cells (average 51%) were 
observed 3∼24 h after APP administration in our investigation. 
This profile is similar to that observed in cases of articular 
disorders, whether inflammatory or infectious in nature, 
especially the relative number of polymorphonuclear cells 
[16,37]. Comparable increases were previously reported by 
others within 8 h after injury [11,32] accompanied by increased 
PGE2 levels, which is also in agreement with our findings. 
Nevertheless, at 24∼48 h all these parameters were back to 
baseline levels and no further changes were observed during the 
prolonged-phase protocol.
Similar results were obtained for total protein. The initial 
concentration was in the normal range [22] expressed as urea 
ratios to compensate for possible fluid volume changes [19]. 
This level increased twice in 6 h before returning to baseline 
concentrations afterwards.
Carmalt et al. [8] reported TNF- as one of the first cytokines 
to be secreted after joint injury with levels peaking in a few 
hours. On the other hand, Billinghurst et al. [5] found no 
difference in synovial fluid TNF- concentrations of healthy 
and diseased joints. In the present study, no significant changes 
in TNF- levels were observed after APP or saline administration. 
This finding supports the notion that TNF- concentrations in 
synovial fluid do not always correlate with the presence of 
lesions, and corroborate the proposed low specificity of this 
biomarker [21].
IL-1 is a major cytokine that induces the synthesis of 
enzymes and inflammatory mediators. It is found at high 
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Fig. 4. Nucleated cell counts (WBC, cell/L) and concentrations (expressed as average ± SE) of total protein, PGE2, and CS for the 
APP-treated and saline-injected groups during the prolonged-phase protocol (0∼28 days). All concentrations are expressed as urea 
ratios to correct for possible fluid volume variations. *Statistically significant differences compared to the saline-tinjected (control) 
group (p < 0.05). †Statistically significant differences compared to the baseline levels for each group (p < 0.05).
concentrations in the synovial fluid of inflamed joints [27]. We 
did not detect IL-1 in any of our samples. This is somewhat 
surprising. However, only healthy animals were enrolled in our 
study and the haemoderivative we used did not contain 
detectable levels of IL-1 after processing. Therefore, the 
absence of significant amounts of IL-1 suggests that no 
significant inflammatory reaction occurred. However, Kamm 
et al. [18] did not find IL-1 in synovial fluid, even in 
osteoarthritis-affected joints, and attributed this result to the 
low sensitivity of the kit that was used. This could also be the 
case in the present study. 
As previously mentioned, IL-1ra is a physiological antagonist 
of IL-1 that competes for the IL-1 receptor. Haemoderivatives 
enriched in IL-1ra have been prepared by different procedures. 
Among the most frequently used for horses are irap and IRAP-II 
devices. Hrara et al. [17] reported increased IL-1ra levels in 
serum obtained after 24 h of blood clotting and irap (200 times) 
while IRAP-II products had IL-1ra levels that were increased 
300 times. Moreover, these authors modified the ELISA kit 
recommendations to improve assay sensitivity. In the present 
study, we used an R&D Systems ELISA kit previously 
validated for horses to quantify IL-1ra levels. The IL-1ra 
concentration in unprocessed plasma was below the assay 
detection levels (< 4 pg/mL, Table 1). After plasma processing 
(to acquire APP), the IL-1ra concentration was ∼130 pg/mL, 
representing an increase more than 100-fold. However, in 
contrast to IRAP-II processed serum in which IL-1 
concentrations also increase [17], IL-1 levels in our 
preparations remained below the ELISA detection levels.
Curiously, APP-treated and saline-injected joints exhibited 
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increased IL-1ra concentrations at 24 h. This increase was 
initially observed in the APP group beginning at 3 h, but not for 
the saline group. This early increase could be due to exogenous 
IL-1ra present in the administered APP. 
Rutgers et al. [33] also measured the cytokine levels in the 
synovial fluid 3 days after injection. This group failed to detect 
significant changes in cytokine concentrations despite repeated 
ACS administration. This finding is consistent with results from 
our study despite differences in the methods of blood derivative 
production. 
In the present study, HA concentrations did not vary upon 
either APP or saline treatment throughout the experimental 
periods of both protocols. Others have also found a poor 
correlation between HA concentration and the presence of 
inflammation in joints [13,38]. In contrast, increased 
concentrations of sulphated GAGs in synovial fluid that 
accompanies articular disease is predominantly due to elevated 
CS levels [2,23,28]. Thus, CS is a useful marker for early 
diagnosis of joint disease. The incremental increase of CS 
concentration observed 24 h after intra-articular APP injection 
is consistent with previously reported increases by other groups 
during articular inflammation [2,12,23]. The low CS levels in 
the synovial fluid samples suggest that neither APP nor saline (or 
arthrocentesis per se) induced significant cartilage destruction.
In conclusion, findings from this study highlight the 
importance of combining short- and long-term observation 
protocols to achieve accurate evaluation of haemoderivatives 
currently used for equine orthopaedic therapeutics. APP has 
proven to be a safe option for treating equine articular diseases. 
Clinical trials are currently being conducted to further evaluate 
the effects of this haemoderivative.
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